UCB SA (UCB) - Total Assets

Latest as of December 2025: €18.16 Billion EUR ≈ $21.23 Billion USD

Based on the latest financial reports, UCB SA (UCB) holds total assets worth €18.16 Billion EUR (≈ $21.23 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore UCB SA cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

UCB SA - Total Assets Trend (2000–2025)

This chart illustrates how UCB SA's total assets have evolved over time, based on quarterly financial data. See UCB total equity for net asset value and shareholders' equity analysis.

UCB SA - Asset Composition Analysis

Current Asset Composition (December 2025)

UCB SA's total assets of €18.16 Billion consist of 33.3% current assets and 66.7% non-current assets.

Asset Category	Amount (EUR)	% of Total Assets
Cash & Equivalents	€0.00	12.4%
Accounts Receivable	€1.79 Billion	9.8%
Inventory	€1.50 Billion	8.2%
Property, Plant & Equipment	€0.00	0.0%
Intangible Assets	€3.45 Billion	19.0%
Goodwill	€5.09 Billion	28.0%

Asset Composition Trend (2000–2025)

This chart illustrates how UCB SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see UCB market cap.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: UCB SA's current assets represent 33.3% of total assets in 2025, an increase from 0.0% in 2000.
Cash Position: Cash and equivalents constituted 12.4% of total assets in 2025, up from 4.7% in 2000.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 46.0% of total assets, an increase from 4.0% in 2000.
Asset Diversification: The largest asset category is goodwill at 28.0% of total assets.

UCB SA Competitors by Total Assets

Key competitors of UCB SA based on total assets are shown below.

Company	Country	Total Assets
Halozyme Therapeutics Inc NASDAQ:HALO	USA	$2.22 Billion
Biomarin Pharmaceutical Inc NASDAQ:BMRN	USA	$8.59 Billion
argenx NV ADR NASDAQ:ARGX	USA	$8.68 Billion
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	China	CN¥8.59 Billion
Asymchem Laboratories Tian Jin Co Ltd SHE:002821	China	CN¥20.70 Billion
Amicus Therapeutics Inc NASDAQ:FOLD	USA	$949.87 Million
Sk Biopharmaceuticals Co Ltd KO:326030	Korea	₩1.20 Trillion
Xiamen Amoytop Biotech Co Ltd SHG:688278	China	CN¥3.21 Billion

UCB SA - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	1.38	1.36	1.27
Quick Ratio	1.04	0.99	0.97
Cash Ratio	0.00	0.00	0.00
Working Capital	€1.65 Billion	€1.26 Billion	€768.00 Million

UCB SA - Advanced Valuation Insights

This section examines the relationship between UCB SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	4.55
Latest Market Cap to Assets Ratio	2.61
Asset Growth Rate (YoY)	4.7%
Total Assets	€18.16 Billion
Market Capitalization	$47.34 Billion USD

Valuation Analysis

Premium Asset Valuation: The market values UCB SA's assets at a significant premium (2.61x), suggesting investors see substantial growth potential or unique competitive advantages.

Positive Asset Growth: UCB SA's assets grew by 4.7% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for UCB SA (2000–2025)

The table below shows the annual total assets of UCB SA from 2000 to 2025.

Year	Total Assets	Change
2025-12-31	€18.16 Billion ≈ $21.23 Billion	+4.68%
2024-12-31	€17.35 Billion ≈ $20.28 Billion	+11.64%
2023-12-31	€15.54 Billion ≈ $18.17 Billion	-2.07%
2022-12-31	€15.87 Billion ≈ $18.55 Billion	+11.67%
2021-12-31	€14.21 Billion ≈ $16.61 Billion	+6.69%
2020-12-31	€13.32 Billion ≈ $15.57 Billion	+20.20%
2019-12-31	€11.08 Billion ≈ $12.95 Billion	+5.39%
2018-12-31	€10.51 Billion ≈ $12.29 Billion	+6.02%
2017-12-31	€9.92 Billion ≈ $11.59 Billion	-2.89%
2016-12-31	€10.21 Billion ≈ $11.94 Billion	-6.79%
2015-12-31	€10.96 Billion ≈ $12.81 Billion	+7.96%
2014-12-31	€10.15 Billion ≈ $11.86 Billion	+3.98%
2013-12-31	€9.76 Billion ≈ $11.41 Billion	+4.27%
2012-12-31	€9.36 Billion ≈ $10.94 Billion	+1.98%
2011-12-31	€9.18 Billion ≈ $10.73 Billion	+2.33%
2010-12-31	€8.97 Billion ≈ $10.49 Billion	-1.66%
2009-12-31	€9.12 Billion ≈ $10.66 Billion	-4.24%
2008-12-31	€9.52 Billion ≈ $11.13 Billion	-0.32%
2007-12-31	€9.55 Billion ≈ $11.17 Billion	-8.98%
2006-12-31	€10.50 Billion ≈ $12.27 Billion	+122.56%
2005-12-31	€4.72 Billion ≈ $5.51 Billion	-12.22%
2004-12-31	€5.37 Billion ≈ $6.28 Billion	+73.85%
2003-12-31	€3.09 Billion ≈ $3.61 Billion	+17.93%
2002-12-31	€2.62 Billion ≈ $3.06 Billion	+2.23%
2001-12-31	€2.56 Billion ≈ $3.00 Billion	+11.32%
2000-12-31	€2.30 Billion ≈ $2.69 Billion	--

About UCB SA

BR:UCB Belgium Biotechnology

Market Cap

$54.15 Billion

€46.31 Billion EUR

Market Cap Rank

#564 Global

#3 in Belgium

Share Price

€243.30

Change (1 day)

-0.25%

52-Week Range

€178.15 - €285.40

All Time High

€285.40